Genmab A/S's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.32.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Genmab A/S is 8.94, ranking 19 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.06B, representing a year-over-year increase of 18.00%, while its net profit experienced a year-over-year increase of 94.21%.
Key Metrics
The current valuation score of Genmab A/S is 8.00, ranking 69 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 16.85, which is 13.56% below the recent high of 19.14 and 94.01% above the recent low of 1.01.
The current earnings forecast score of Genmab A/S is 8.46, ranking 122 out of 391 in the Biotechnology & Medical Research industry. The average price target is 34.70, with a high of 48.00 and a low of 23.50.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Genmab A/S is 6.80, ranking 174 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 28.99 and the support level at 24.09, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Genmab A/S is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 10.64%, representing a quarter-over-quarter increase of 1.02%. The largest institutional shareholder is James Simons, holding a total of 3.49M shares, representing 0.57% of shares outstanding, with 58.68% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Genmab A/S is 8.54, ranking 4 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
